Key Takeaways
- Bliss GVS acquisition closed, reshaping the group: The deal completed September 28, 2026, giving Anupam ~50% control and adding a pharma formulations platform that management expects will reduce overall revenue cyclicality over the next four to eight quarters.
- Margins jumped, but management urges caution: Consolidated EBITDA margin hit 25% in Q2 (vs 19% a year ago), and standalone touched 34%, yet the company explicitly guides investors back to 24–26% for standalone and 22–24% for Bliss on a sustained basis, citing product-mix timing.
- A six-year metal contract proves the platform thesis: A new U.S.-based specialty metal manufacturer signed a long-term supply deal after Anupam commercialized the product in just four months, a win management attributes to its strategy of keeping multipurpose capacity free.
- H2 revenue guided at ₹2,400–₹2,500 crores: That implies a consolidated annualized run rate of roughly ₹4,800–₹5,000 crores, with organic growth from there pegged at 20–25% over a three-to-five-year horizon.
- What to watch next quarter: Whether Bliss CDMO discussions convert into disclosed wins, progress on the API acquisition target, and any margin normalization toward guided ranges as the product mix shifts.
The Bliss GVS Acquisition: Rationale, Margins & Synergies
- Platform now spans the pharma value chain: Anupam’s KSMs and specialty chemical capabilities feed into Bliss’s formulations business, while Bliss adds regulated-market access across Europe and Africa; the missing API piece is an active M&A target.
- Synergy timeline is taking shape: CDMO conversations are already active, supply-side sourcing synergies are being mapped, and end-market support in the U.S. and Europe is underway; management expects to see momentum in three to four quarters.
- Bliss margin performance was strong, but not the new baseline: Operating EBITDA ran at 26.2% in H1 on sales of higher-margin products and successful price-rise pass-through; management guides 22–24% on a sustained basis and will not commit to the higher run rate.
- Bliss capacity utilization is still in the 40s, with meaningful year-on-year growth, leaving headroom as the CDMO pipeline converts.
- Bliss disclosure is constrained: Because Bliss is a separately listed entity, management declined to quantify CDMO growth, break out molecule-by-molecule filing status, or comment on seasonality, though it will urge Bliss to hold its own calls soon.
Thakkar: “I think what we can say is that the active Bliss, yes, we believe that 22%-24% EBITDA margin, which we have said is an average consolidated EBITDA margin for Anupam as well, on a consolidated basis. I think that is the number that we should be looking for.”
Standalone Performance & the Margin Story
- Revenue decline is optical: The Q2 FY27 vs Q2 FY26 standalone revenue drop reflects a one-time ~₹180 crore sale in the base quarter; excluding that, the underlying business is at a normalized run rate.
- Standalone EBITDA margin hit 34%, well above the 24–26% guidance range, driven by the specific product portfolio sold in the quarter; management explicitly urges caution and asks investors to stick with the earlier guided range.
- Inventory strategy insulates margins from raw-material swings: High inventory acts as a shock absorber so customers are not exposed to input price volatility; the business earns its margin from technical capability, not from trading raw materials, and has delivered consistent EBITDA margins across the last four to five cycles.
Thakkar: “Tanya, yes, we have done better on the margins, but it is also to do with the product portfolio and the products that we have sold in this quarter versus the other quarters. I would urge to caution and continue to guide at the numbers that we have been guiding.”
New Business Wins & the Order Book
- Six-year metal contract validates the speed-to-market strategy: A U.S.-based global specialty metal manufacturer needed an urgent product; Anupam’s technical team built and commercialized it in four months, converting the inquiry into a six-year long-term supply agreement and marking entry into a new geological-resources segment.
- The contract scales quickly: The balance of FY27 is expected at ₹100–₹150 crores, with the monthly run rate potentially doubling over the next year to year and a half.
- Order book ramp-up is accelerating: Last year’s order book contributed ~₹350 crores; this year management expects 1.8x–2x that figure, with a path to the average annual number of ~₹2,500 crores over the next two to three years.
- Elementium is on schedule: Monthly supply volumes to customers have begun, and contract discussions are ongoing with a conclusion expected soon.
Thakkar: “In a matter of just four months' time from start to now, we have been able to convert them into a six-year long-term contract, which is something which I think is very high reflective of our capabilities, that you can get a product approved in three months' time from inquiry and get a contract of six years.”
Platform Strategy & the Cyclicality Play
- The group is building a deliberately diversified platform: Across chemistries (fluorination to formulation), geographies (U.S., Europe, Japan, India, Africa), end markets (pharma, polymer, agro, EV and semiconductor Performance Materials), and the full value chain from basic raw materials like HF and KF through to APIs and polymers.
- Revenue cyclicality should decline as the mix shifts: As Pharma and Performance Materials grow their share of group revenue, management expects cyclicality to reduce over the next four to eight quarters.
- Jayhawk is already unlocking demand: One Japanese customer indicated it could triple volumes if material is supplied out of Jayhawk, showing how geographic diversification directly expands the wallet share with existing accounts.
- Jayhawk margin improvement has three workstreams: Process optimization with cross-learning from each other, sourcing raw materials from India at scale, and improving effluent treatment cost.
Thakkar: “If you look at from across, so if you look at the whole strategy here, across chemistries, across geographies, like U.S., Europe, Japan, India, and Africa, across end markets like pharma, polymer, agro, and Performance Materials like your products going into EV and semiconductor industry, across right from a very basic raw material like HF, KF for a nitrobenzene to AI or an API or a formulation or a polymer, is something which is very unique that we are building.”
Cash Flow, Working Capital & Capital Allocation
- H1 operating cash flow nearly matched all of FY26: ₹328 crores in H1 FY27 vs ₹334 crores for the full year FY26, driven by stronger profitability and a working capital focus.
- Working capital days improved slightly: Excluding the Bliss GVS balance sheet, the cycle moved from 276 days to 271 days, with management committed to further improvement in inventory management and receivables collection.
- Cash will be held at entity level: Reasonable cushions will be maintained in each entity to support working capital and minor capex, rather than swept to a central pool.
- M&A focus remains on the API gap: Management is actively evaluating alternatives and having conversations to plug the API piece of the pharma value chain, but has nothing to share publicly at this stage.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated H2 FY27 revenue | ₹2,400–₹2,500 crores, implying ~₹4,800–₹5,000 crores annualized run rate | H2 FY27 |
| Organic growth from H2 run rate | 20–25 percentage points | Near-term three-to-five-year period |
| Standalone EBITDA margin | 24–26% (despite current 34%, management urges reversion to this range) | Sustained basis |
| Bliss GVS steady-state EBITDA margin | 22–24% | Sustained basis |
| Revenue cyclicality reduction | Cyclicality to decline as Pharma and Performance Materials mix grows | Next four to eight quarters |
| Bliss synergy momentum | CDMO and supply-side benefits to begin showing | Three to four quarters |
| New metal contract: FY27 balance | At least ₹100–₹150 crores | FY27 |
| New metal contract: run-rate ramp | Monthly run rate can double | Next year to year and a half |
| Order book ramp-up | 1.8x–2x of last year’s ~₹350 crores, scaling to ~₹2,500 crores average annual number | This year, then two to three years |
| Elementium contract conclusion | Discussions ongoing, expected to conclude soon | No fixed date |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Total income | ₹821 cr, +11% YoY |
| EBITDA | ₹202 cr, +41% YoY |
| EBITDA margin | ~25%, vs 19.4% in Q2 FY26 |
| Profit after tax | ₹65 cr, +14% YoY |
| PAT margin | ~8% |
| H1 FY27 total income | ₹1,489 cr, +21% YoY |
| H1 FY27 EBITDA | ₹377 cr, +38% YoY |
| H1 FY27 EBITDA margin | 25.5%, vs 22.2% in H1 FY26 |
| H1 FY27 PAT | ₹116 cr, +10% YoY |
| H1 FY27 operating cash flow | ₹328 cr, vs ₹334 cr in full year FY26 |
| Revenue mix: Life science specialty chemicals | 42% of Q2 revenue |
| Revenue mix: Performance Materials | 28% of Q2 revenue |
| Revenue mix: Other fluorinated products | 29% of Q2 revenue |
| Cumulative LOIs and long-term contracts | ~₹17,496 cr, providing multi-year visibility |
| H2 FY27 consolidated revenue guidance | ₹2,400–₹2,500 cr, implying annualized run rate of ₹4,800–₹5,000 cr |
| Organic growth expectation (3–5 year) | 20–25% |
| Working capital cycle (ex-Bliss GVS) | 271 days, improved from 276 days |
| Bliss GVS Pharma stake acquired | 50.07% equity capital |
| Bliss GVS revenue contribution in Q2 | 3 days only, consolidated from acquisition date of 28 Sep 2026 |
| Bliss GVS capacity utilization | In the 40s (percent) |
| Bliss GVS steady-state EBITDA margin guidance | 22–24% |
| New US specialty metal contract: expected FY27 contribution | ₹100–₹150 cr, supply starting November |
| Order book revenue in FY26 | ~₹350 cr, expected to reach 1.8x–2x in FY27 |
| CRISIL ESG rating | "Strong" 62, up from "Adequate" 54 |